A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Phase 1 Clinical Trial to Evaluate the Safety/Tolerability and PK Characteristics, and to Explore Food Effect and Ethnic Difference of JW2286 in Healthy Volunteers
Latest Information Update: 17 Jan 2025
At a glance
- Drugs JW 2286 (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
Most Recent Events
- 13 Jan 2025 Status changed from not yet recruiting to recruiting.
- 27 Nov 2024 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health;NCT06703710).
- 27 Nov 2024 Status changed from planning to not yet recruiting.